|
NZ219575A
(en)
|
1986-03-12 |
1990-04-26 |
Glaxo Group Ltd |
Phosphate, substituted alkoxy, or amino-carbonyloxy derivatives of milbemycin, and pesticidal compositions
|
|
WO1991011457A1
(en)
|
1990-01-24 |
1991-08-08 |
Buckley Douglas I |
Glp-1 analogs useful for diabetes treatment
|
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
|
SG52542A1
(en)
|
1993-03-29 |
1998-09-28 |
Univ Cincinnati |
Analogs of peptide yy and uses thereof
|
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
|
WO1995033474A1
(en)
|
1994-06-03 |
1995-12-14 |
Tsumura & Co. |
Medicinal composition
|
|
US5512549A
(en)
|
1994-10-18 |
1996-04-30 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
|
|
US5574010A
(en)
|
1994-11-14 |
1996-11-12 |
The Regents Of The University Of California |
Treatment of pancreatic tumors with peptide YY and analogs thereof
|
|
US5869602A
(en)
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
|
BR9604880A
(pt)
|
1995-03-31 |
1998-05-19 |
Emisphere Tech Inc |
Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
|
|
US5650386A
(en)
|
1995-03-31 |
1997-07-22 |
Emisphere Technologies, Inc. |
Compositions for oral delivery of active agents
|
|
US5866536A
(en)
|
1995-03-31 |
1999-02-02 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
SE9600070D0
(sv)
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral pharmaceutical dosage forms
|
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
DK0944648T3
(da)
|
1996-08-30 |
2007-07-02 |
Novo Nordisk As |
GLP-1 derivater
|
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
ATE366584T1
(de)
|
1996-11-12 |
2007-08-15 |
Novo Nordisk As |
Verwendung von glp-1 peptiden
|
|
WO1998020885A1
(en)
|
1996-11-13 |
1998-05-22 |
University Of Cincinnati |
Analogs of peptide yy and uses thereof
|
|
US5773647A
(en)
|
1997-02-07 |
1998-06-30 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
EP0908515A3
(en)
|
1997-09-16 |
2000-04-26 |
Smithkline Beecham Plc |
Pancreatic polypeptide
|
|
AU3247799A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
|
EP1056774A1
(en)
|
1998-02-27 |
2000-12-06 |
Novo Nordisk A/S |
N-terminally truncated glp-1 derivatives
|
|
JP2002512175A
(ja)
|
1998-02-27 |
2002-04-23 |
ノボ ノルディスク アクティーゼルスカブ |
Ｇｌｐ−１類似体の誘導体類
|
|
WO1999043707A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
N-terminally modified glp-1 derivatives
|
|
US6046167A
(en)
|
1998-03-25 |
2000-04-04 |
University Of Cincinnati |
Peptide YY analogs
|
|
AU4317899A
(en)
|
1998-06-08 |
1999-12-30 |
Schering Corporation |
Neuropeptide y5 receptor antagonists
|
|
SE9802080D0
(sv)
|
1998-06-11 |
1998-06-11 |
Hellstroem |
Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
|
|
EP1100530B1
(en)
|
1998-07-31 |
2003-10-08 |
Novo Nordisk A/S |
In-vitro stimulation of beta cell proliferation
|
|
MY155270A
(en)
|
1998-09-24 |
2015-09-30 |
Lilly Co Eli |
Use of glp-1 or analogs in treatment of stroke
|
|
AU762012B2
(en)
|
1998-12-07 |
2003-06-19 |
Ipsen Pharma S.A.S. |
Analogues of GLP-1
|
|
WO2000046182A1
(en)
|
1999-02-05 |
2000-08-10 |
Emisphere Technologies, Inc. |
Method of preparing alkylated salicylamides
|
|
ATE386508T1
(de)
|
1999-02-22 |
2008-03-15 |
Merrion Res I Ltd |
Feste orale dosierungsform enthaltend einen resorptionsverstärker
|
|
WO2000048589A1
(en)
|
1999-02-22 |
2000-08-24 |
Emisphere Holdings, Inc. |
Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
|
|
US7658938B2
(en)
|
1999-02-22 |
2010-02-09 |
Merrion Reasearch III Limited |
Solid oral dosage form containing an enhancer
|
|
BR0010705A
(pt)
|
1999-04-30 |
2002-02-05 |
Amylin Pharmaceuticals Inc |
Exendinas modificadas e agonistas da exendina
|
|
ATE252601T1
(de)
|
1999-05-17 |
2003-11-15 |
Conjuchem Inc |
Lang wirkende insulinotrope peptide
|
|
US7601691B2
(en)
|
1999-05-17 |
2009-10-13 |
Conjuchem Biotechnologies Inc. |
Anti-obesity agents
|
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
GB9923436D0
(en)
|
1999-10-04 |
1999-12-08 |
American Home Prod |
Pharmaceutical compositions
|
|
US6793934B1
(en)
|
1999-12-08 |
2004-09-21 |
Shire Laboratories, Inc. |
Solid oral dosage form
|
|
AU2001275231A1
(en)
|
2000-06-02 |
2001-12-11 |
Emisphere Technologies, Inc. |
Method of preparing salicylamides
|
|
US7049283B2
(en)
|
2000-12-06 |
2006-05-23 |
Novartis Ag |
Pharmaceutical compositions for the oral delivery of pharmacologically active agents
|
|
SK288342B6
(en)
|
2000-12-07 |
2016-03-01 |
Lilly Co Eli |
GLP-1 fusion proteins
|
|
MXPA03005135A
(es)
|
2000-12-13 |
2003-12-04 |
Lilly Co Eli |
Regimen de tratamiento cronico usando peptidos insulinotropicos similares al glucagon.
|
|
EP1351984A2
(en)
|
2000-12-13 |
2003-10-15 |
Eli Lilly And Company |
Amidated glucagon-like peptide-1
|
|
US8273713B2
(en)
|
2000-12-14 |
2012-09-25 |
Amylin Pharmaceuticals, Llc |
Methods of treating obesity using PYY[3-36]
|
|
GB0102075D0
(en)
|
2001-01-26 |
2001-03-14 |
Astrazeneca Ab |
Process
|
|
US6589938B2
(en)
|
2001-06-29 |
2003-07-08 |
National University Of Singapore |
Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
|
|
US20030068356A1
(en)
|
2001-07-10 |
2003-04-10 |
Pather S. Indiran |
Sequential drug delivery systems
|
|
AU2002317599B2
(en)
|
2001-07-31 |
2008-04-03 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
GLP-1 exendin-4 peptide analogs and uses thereof
|
|
AU2002332054B2
(en)
|
2001-09-24 |
2007-11-08 |
Imperial Innovations Limited |
Modification of feeding behavior
|
|
CA2466863A1
(en)
|
2001-11-29 |
2003-06-05 |
Emisphere Technologies, Inc. |
Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid
|
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
|
AU2003201146B2
(en)
|
2002-02-01 |
2008-04-17 |
Pfizer Products Inc. |
Dry granulated formulations of azithromycin
|
|
NZ534125A
(en)
|
2002-02-20 |
2006-11-30 |
Emisphere Tech Inc |
A formulation comprising a GLP-1 compound and a delivery agent
|
|
EP1525219B1
(en)
|
2002-07-04 |
2009-05-27 |
Zealand Pharma A/S |
Glp-1 and methods for treating diabetes
|
|
JP2004131398A
(ja)
|
2002-10-08 |
2004-04-30 |
Taihei Chemical Industrial Co Ltd |
錠剤用滑沢剤
|
|
EP1583549A4
(en)
|
2003-01-17 |
2006-10-04 |
Sod Conseils Rech Applic |
YY PEPTIDE ANALOGS
|
|
WO2004067548A2
(en)
|
2003-01-31 |
2004-08-12 |
Theratechnologies Inc. |
Chemically modified metabolites of regulatory peptides and methods of producing and using same
|
|
JP2006520818A
(ja)
|
2003-03-19 |
2006-09-14 |
イーライ リリー アンド カンパニー |
ポリエチレングリコール結合ｇｌｐ−１化合物
|
|
CA2525168A1
(en)
|
2003-05-14 |
2004-12-02 |
Emisphere Technologies, Inc. |
Compositions for delivering peptide yy and pyy agonists
|
|
US7572581B2
(en)
|
2003-06-30 |
2009-08-11 |
Roche Molecular Systems, Inc. |
2′-terminator nucleotide-related methods and systems
|
|
BRPI0412458A
(pt)
|
2003-07-11 |
2006-10-17 |
Novartis Ag |
composições farmacêuticas oralmente dosadas compreendendo um agente de liberação na forma micronizada
|
|
JP2007501811A
(ja)
|
2003-08-08 |
2007-02-01 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
治療的な関心対象のタンパク質に対する遅延分子の選択的な化学物質接合のためのガラクトースオキシダーゼの使用。
|
|
CN101380476A
(zh)
|
2003-09-19 |
2009-03-11 |
诺沃挪第克公司 |
治疗肽的清蛋白结合型衍生物
|
|
EP1670515A2
(en)
|
2003-09-19 |
2006-06-21 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
|
JP2007537981A
(ja)
|
2003-09-19 |
2007-12-27 |
ノボ ノルディスク アクティーゼルスカブ |
新規の血漿タンパク質親和性タグ
|
|
SI1687019T1
(en)
|
2003-11-20 |
2018-04-30 |
Novo Nordisk A/S |
Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
|
|
KR20060109940A
(ko)
|
2003-12-18 |
2006-10-23 |
노보 노르디스크 에이/에스 |
알부민-유사제에 연결된 신규 ｇｌｐ-1 유사체
|
|
RU2006120079A
(ru)
|
2003-12-18 |
2008-01-27 |
Ново Нордиск А/С (DK) |
Производные глюкагоноподобного пептида-1 (glp-1)
|
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
|
AU2005211755B2
(en)
|
2004-02-11 |
2012-03-15 |
Amylin Pharmaceuticals, Llc |
Hybrid polypeptides with selectable properties
|
|
EP2335715A3
(en)
|
2004-02-11 |
2013-12-18 |
Amylin Pharmaceuticals, LLC |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
|
BRPI0507585A
(pt)
|
2004-03-17 |
2007-07-03 |
7Tm Pharmas As |
agonistas seletivos do receptor y2 para intervenções terapêuticas
|
|
EP1786458A2
(en)
|
2004-03-17 |
2007-05-23 |
7TM Pharma A/S |
Y2/y4 selective receptor agonists for therapeutic interventions
|
|
CA2560174A1
(en)
|
2004-03-17 |
2005-09-29 |
7Tm Pharma A/S |
Y4 selective receptor agonists for therapeutic interventions
|
|
US20090186811A1
(en)
|
2004-03-17 |
2009-07-23 |
Thue Schwartz |
Y2 Selective Receptor Agonists for Therapeutic Interventions
|
|
WO2005099672A1
(en)
|
2004-04-13 |
2005-10-27 |
Ranbaxy Laboratories Limited |
A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
|
|
KR20070008720A
(ko)
|
2004-05-06 |
2007-01-17 |
에미스페어 테크놀로지스, 인코포레이티드 |
습윤 헤파린의 고체 투여형
|
|
EA013518B1
(ru)
|
2004-05-06 |
2010-06-30 |
Эмисфире Текнолоджис, Инк. |
Кристаллические полиморфные формы n-[8-(2-гидроксибензоил)амино]каприлата натрия
|
|
CA2565188C
(en)
|
2004-05-14 |
2014-03-04 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
GB0412181D0
(en)
|
2004-06-01 |
2004-06-30 |
Celltech R&D Ltd |
Biological products
|
|
WO2005121090A1
(en)
|
2004-06-02 |
2005-12-22 |
Abbott Laboratories |
Substituted piperidines that have antiangiogenic activity
|
|
CN101010339B
(zh)
|
2004-07-02 |
2011-11-09 |
布里斯托尔-迈尔斯斯奎布公司 |
人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
|
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
|
EP1765408B1
(en)
|
2004-07-08 |
2015-12-09 |
Novo Nordisk A/S |
Polypeptide protracting tags comprising a tetrazole moiety
|
|
NZ552558A
(en)
|
2004-07-12 |
2009-11-27 |
Emisphere Tech Inc |
Compositions for delivering peptide YY and PYY agonists
|
|
WO2006020207A2
(en)
|
2004-07-19 |
2006-02-23 |
University Of Cincinnati |
Compounds for control of appetite
|
|
WO2006124047A2
(en)
|
2004-08-13 |
2006-11-23 |
Emisphere Technologies, Inc. |
Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
|
|
WO2006049681A2
(en)
|
2004-08-30 |
2006-05-11 |
Bayer Pharmaceuticals Corporation |
Selective neuropeptide y2 receptor agonists
|
|
US7893017B2
(en)
|
2004-10-07 |
2011-02-22 |
Novo Nordisk A/S |
Protracted GLP-1 compounds
|
|
US7410949B2
(en)
|
2005-01-18 |
2008-08-12 |
Hoffmann-La Roche Inc. |
Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
|
|
ES2540929T3
(es)
|
2005-02-01 |
2015-07-14 |
Emisphere Technologies, Inc. |
Sistema de administración de retención gástrica y liberación controlada
|
|
EP2256130B1
(en)
|
2005-02-02 |
2013-09-25 |
Novo Nordisk A/S |
Novel insulin derivatives
|
|
JP2008531059A
(ja)
|
2005-03-04 |
2008-08-14 |
バイオレクシス ファーマシューティカル コーポレーション |
改変トランスフェリン融合タンパク質
|
|
GB0504857D0
(en)
|
2005-03-09 |
2005-04-13 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
|
JP5755398B2
(ja)
|
2005-03-18 |
2015-07-29 |
ノヴォ ノルディスク アー／エス |
伸長されたｇｌｐ−１化合物
|
|
TWI372629B
(en)
|
2005-03-18 |
2012-09-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
|
WO2006097535A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
|
EP1863537A2
(en)
|
2005-03-18 |
2007-12-12 |
Novo Nordisk A/S |
Dimeric peptide agonists of the glp-1 receptor
|
|
CA2603105A1
(en)
|
2005-03-28 |
2006-10-05 |
Dexcel Pharma Technologies Ltd. |
Controlled absorption of statins in the intestine
|
|
TW200716679A
(en)
|
2005-05-26 |
2007-05-01 |
Bristol Myers Squibb Co |
N-terminally modified GLP-1 receptor modulators
|
|
WO2007008778A2
(en)
|
2005-07-11 |
2007-01-18 |
Nastech Pharmaceutical Company Inc. |
Formulations for enhanced mucosal delivery of pyy
|
|
WO2007011958A2
(en)
|
2005-07-15 |
2007-01-25 |
Emisphere Technologies, Inc. |
Intraoral dosage forms of glucagon
|
|
WO2007009894A2
(en)
|
2005-07-18 |
2007-01-25 |
Novo Nordisk A/S |
Peptides for use in the treatment of obesity
|
|
SI3524261T1
(sl)
|
2005-08-19 |
2024-02-29 |
Amylin Pharmaceuticals, Llc |
Exendin za uporabo pri zdravljenju sladkorne bolezni in zmanjševanju telesne teže
|
|
US20070049557A1
(en)
|
2005-08-24 |
2007-03-01 |
Hashim Ahmed |
Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
|
|
AU2005337101A1
(en)
|
2005-09-21 |
2007-04-12 |
7Tm Pharma A/S |
Y2 selective receptor agonists for therapeutic interventions
|
|
US8022035B2
(en)
|
2005-09-21 |
2011-09-20 |
7Tm Pharma A/S |
Y4 selective receptor agonists for therapeutic interventions
|
|
WO2007061434A2
(en)
|
2005-11-10 |
2007-05-31 |
Nastech Pharmaceutical Company Inc. |
A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
|
|
KR101432313B1
(ko)
|
2005-11-17 |
2014-08-20 |
노파르티스 아게 |
약제학적 조성물
|
|
WO2007065808A2
(en)
|
2005-12-07 |
2007-06-14 |
F. Hoffmann-La Roche Ag |
Neuropeptide-2 receptor-agonists
|
|
RU2008124109A
(ru)
|
2005-12-08 |
2010-01-20 |
МДРНА, Инк. (US) |
Чресслизистая доставка стабилизированных композиций эксендина
|
|
EP1963343A1
(en)
|
2005-12-14 |
2008-09-03 |
Novo Nordisk A/S |
Polypeptide protracting tags
|
|
US20070197445A1
(en)
|
2006-01-18 |
2007-08-23 |
University Of Cincinnati |
Compounds for control of appetite
|
|
JP5412273B2
(ja)
|
2006-03-21 |
2014-02-12 |
アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー |
ペプチド−ぺプチダーゼ阻害剤及びその使用
|
|
CN105232482A
(zh)
|
2006-04-07 |
2016-01-13 |
默里昂研究Iii有限公司 |
包含增强剂的固体口服剂型
|
|
WO2007121318A2
(en)
|
2006-04-12 |
2007-10-25 |
Emisphere Technologies, Inc. |
Formulations for delivering insulin
|
|
AU2007247109B2
(en)
|
2006-05-09 |
2012-03-15 |
Novo Nordisk A/S |
Insulin derivative
|
|
EP2040731A4
(en)
|
2006-06-09 |
2010-05-19 |
Merrion Res Iii Ltd |
SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
|
|
JP5475443B2
(ja)
|
2006-06-28 |
2014-04-16 |
エミスフェアー・テクノロジーズ・インク |
硝酸ガリウム製剤
|
|
GB0613196D0
(en)
|
2006-07-03 |
2006-08-09 |
Imp Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
|
ES2296529B1
(es)
|
2006-08-07 |
2009-04-01 |
Laboratorios Farmaceuticos Rovi, S.A. |
Composicion farmaceutica con promotores de absorcion.
|
|
BRPI0716539A2
(pt)
|
2006-09-07 |
2016-11-01 |
Emisphere Tech Inc |
métodos para sintetização de ácido n-(8-[2-hidroxibenzoil]amino) caprílico e de sal de sódio deste
|
|
WO2008039351A2
(en)
|
2006-09-22 |
2008-04-03 |
Novartis Ag |
Method of manufacturing tablets containing pharmacologically active agents
|
|
BRPI0717098B8
(pt)
|
2006-09-22 |
2021-05-25 |
Novo Nordisk As |
análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação
|
|
GB0621973D0
(en)
|
2006-11-03 |
2006-12-13 |
Philogen Spa |
Binding molecules and uses thereof
|
|
US20100069410A1
(en)
|
2006-12-01 |
2010-03-18 |
Emisphere Technologies Inc. |
acyclovir formulations
|
|
US20090099074A1
(en)
|
2007-01-10 |
2009-04-16 |
Conjuchem Biotechnologies Inc. |
Modulating food intake
|
|
EP2101822A2
(en)
|
2007-01-18 |
2009-09-23 |
Novo Nordisk A/S |
Use of peptides in combination with surgical intervention for the treatment of obesity
|
|
EP2106405A2
(en)
|
2007-01-18 |
2009-10-07 |
Novo Nordisk A/S |
Peptides for use in the treatment of obesity
|
|
EP2131810B1
(en)
|
2007-03-02 |
2011-05-04 |
Novartis AG |
Oral administration of a calcitonin
|
|
GB0708226D0
(en)
|
2007-04-27 |
2007-06-06 |
7Tm Pharma As |
Y-receptor agonists
|
|
EP2171080A4
(en)
|
2007-06-12 |
2010-10-27 |
Glaxosmithkline Llc |
PROCESS FOR DETECTING PROTEIN IN PLASMA
|
|
EP2500432A3
(en)
|
2007-07-09 |
2012-12-19 |
Imperial Innovations Limited |
Analogues of human pancreatic polypeptide (hPP) and their effects on feeding behaviours
|
|
AU2008296444A1
(en)
|
2007-08-29 |
2009-03-12 |
The Regents Of The University Of California |
Salicylanilide modified peptides for use as oral therapeutics
|
|
EP2190460B1
(en)
|
2007-09-05 |
2014-12-17 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
|
WO2009030774A1
(en)
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Truncated glp-1 derivatives and their therapeutical use
|
|
JP5476304B2
(ja)
|
2007-09-05 |
2014-04-23 |
ノボ・ノルデイスク・エー／エス |
グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
|
|
JP5385278B2
(ja)
|
2007-09-11 |
2014-01-08 |
モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト |
単独でまたはグルカゴン様ペプチドと組み合わせて用いる、医薬におけるペプチドｙｙの使用
|
|
US8598314B2
(en)
|
2007-09-27 |
2013-12-03 |
Amylin Pharmaceuticals, Llc |
Peptide-peptidase-inhibitor conjugates and methods of making and using same
|
|
CN101939023B
(zh)
|
2007-10-16 |
2016-08-03 |
百康有限公司 |
可经口给药的固体药物组合物及其方法
|
|
WO2009059188A1
(en)
|
2007-11-02 |
2009-05-07 |
Emisphere Technologies, Inc. |
Method of treating vitamin b12 deficiency
|
|
US20090124639A1
(en)
|
2007-11-06 |
2009-05-14 |
Emisphere Technologies Inc. |
valacyclovir formulations
|
|
US20100317057A1
(en)
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
|
BRPI0912615A2
(pt)
|
2008-05-16 |
2016-01-26 |
Novo Nordisk As |
agonistas de receptor y2 e/ou y4 de longa ação
|
|
NZ591497A
(en)
|
2008-08-18 |
2012-11-30 |
Entera Bio Ltd |
A compositions comprising a protein, a protease inhibitor and N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) or N-(10[2-hydroxybenzoyl]amino)decanoate (SNAD) for diabetes mellitus treatment
|
|
CN102149411A
(zh)
|
2008-09-12 |
2011-08-10 |
诺沃—诺迪斯克有限公司 |
酰化肽或蛋白的方法
|
|
US8299023B2
(en)
|
2008-09-17 |
2012-10-30 |
Hoffmann-La Roche Inc. |
Neuropeptide-2 receptor (Y-2R) agonists
|
|
GB0817067D0
(en)
|
2008-09-18 |
2008-10-22 |
7Tm Pharma As |
Intestinal treatment
|
|
MY156811A
(en)
|
2008-10-15 |
2016-03-31 |
Bayer Corpscience Ag |
Use of dithiine-tetracarboximides for controlling phytopathogenic fungsi
|
|
WO2010052144A2
(en)
|
2008-11-05 |
2010-05-14 |
F. Hoffmann-La Roche Ag |
Neuropeptide-2-receptor (y-2r) agonists and uses thereof
|
|
CN101463081B
(zh)
|
2009-01-12 |
2012-07-04 |
华东师范大学 |
一种glp-1衍生物
|
|
CN106177958A
(zh)
|
2009-02-13 |
2016-12-07 |
勃林格殷格翰国际有限公司 |
包含dpp‑4抑制剂(利拉列汀)任选地组合其它抗糖尿病药的抗糖尿病药物
|
|
MX2011008774A
(es)
|
2009-02-20 |
2011-10-24 |
Ipsen Pharma Sas |
Conjugados citotoxicos que tienen un compuesto de unión de receptores de neuropeptidos y.
|
|
AR077956A1
(es)
|
2009-09-14 |
2011-10-05 |
Bayer Cropscience Ag |
Combinaciones de compuestos activos
|
|
US20130040877A1
(en)
|
2009-09-18 |
2013-02-14 |
Novo Nordisk A/S |
Long-acting y2 receptor agonists
|
|
JP2013507414A
(ja)
|
2009-10-13 |
2013-03-04 |
エフ．ホフマン−ラ ロシュ アーゲー |
神経ペプチド−２受容体（ｙ−２ｒ）アゴニスト
|
|
WO2011058165A1
(en)
|
2009-11-13 |
2011-05-19 |
Novo Nordisk A/S |
Long-acting y2 receptor agonists
|
|
AU2010339907A1
(en)
|
2009-12-16 |
2012-07-05 |
Nod Pharmaceuticals, Inc. |
Compositions and methods for oral drug delivery
|
|
US20110182985A1
(en)
|
2010-01-28 |
2011-07-28 |
Coughlan David C |
Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
|
|
WO2011109787A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Methods of administering insulinotropic peptides
|
|
GB2478849A
(en)
|
2010-03-16 |
2011-09-21 |
Chiasma Inc |
Improved pharmecutical compositions and methods of delivery
|
|
WO2011131646A1
(en)
|
2010-04-20 |
2011-10-27 |
Novo Nordisk A/S |
Long-acting gastrin derivatives
|
|
CN107961377B
(zh)
|
2010-05-05 |
2022-11-22 |
勃林格殷格翰国际有限公司 |
组合疗法
|
|
DE202010015867U1
(de)
|
2010-11-25 |
2011-05-05 |
Buchhalter, Thomas |
Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
|
|
AU2011343190B2
(en)
*
|
2010-12-16 |
2016-12-08 |
Novo Nordisk A/S |
Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
|
|
GB201101459D0
(en)
|
2011-01-27 |
2011-03-16 |
Imp Innovations Ltd |
Novel compounds and thier effects on fedding behaviour
|
|
EP3225631B1
(en)
|
2011-04-12 |
2019-01-09 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
|
JP6006309B2
(ja)
*
|
2011-07-08 |
2016-10-12 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
|
|
ES2715308T3
(es)
|
2012-03-22 |
2019-06-03 |
Novo Nordisk As |
Composiciones que comprenden un agente de suministro y su preparación
|
|
PL3542790T3
(pl)
|
2012-03-22 |
2024-02-26 |
Novo Nordisk A/S |
Kompozycje zawierające substancję dostarczającą i ich przygotowanie
|
|
EP2827885B1
(en)
|
2012-03-22 |
2018-08-15 |
Novo Nordisk A/S |
Compositions of glp-1 peptides and preparation thereof
|
|
US20150141336A1
(en)
|
2012-05-29 |
2015-05-21 |
Novo Nordisk A/S |
Pancreatic Peptide Compounds and Use
|
|
JP6517690B2
(ja)
|
2012-06-20 |
2019-05-22 |
ノヴォ ノルディスク アー／エス |
ペプチド及び送達剤を含む錠剤製剤
|
|
DK2866825T3
(da)
|
2012-07-01 |
2020-06-08 |
Novo Nordisk As |
Anvendelse af langstidsvirkende glp-1-peptider
|
|
PE20151808A1
(es)
|
2013-05-02 |
2015-12-16 |
Glaxosmithkline Ip Dev Ltd |
Peptidos terapeuticos
|
|
MY172578A
(en)
|
2013-05-02 |
2019-12-03 |
Novo Nordisk As |
Oral dosing of glp-1 compounds
|
|
US10583172B2
(en)
|
2013-11-15 |
2020-03-10 |
Novo Nordisk A/S |
HPYY(1-36) having a beta-homoarginine substitution at position 35
|
|
EP3068421B1
(en)
|
2013-11-15 |
2019-04-17 |
Novo Nordisk A/S |
Selective pyy compounds and uses thereof
|
|
MX2017010220A
(es)
|
2015-02-09 |
2018-02-21 |
Entera Bio Ltd |
Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
|
|
MX392572B
(es)
|
2015-06-12 |
2025-03-24 |
Novo Nordisk As |
Compuestos del péptido yy (pyy) selectivos y sus usos.
|
|
CA2997343A1
(en)
|
2015-10-07 |
2017-04-13 |
Cyprumed Gmbh |
Pharmaceutical formulations for the oral delivery of peptide drugs
|
|
AR114353A1
(es)
|
2018-02-02 |
2020-08-26 |
Novo Nordisk As |
Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
|